145 related articles for article (PubMed ID: 30227310)
1. Diagnostic power of VEGF, MMP-9 and TIMP-1 in patients with breast cancer. A multivariate statistical analysis with ROC curve.
Zajkowska M; Gacuta E; Kozłowska S; Lubowicka E; Głażewska EK; Chrostek L; Szmitkowski M; Pawłowski P; Zbucka-Krętowska M; Ławicki S
Adv Med Sci; 2019 Mar; 64(1):1-8. PubMed ID: 30227310
[TBL] [Abstract][Full Text] [Related]
2. Human Plasma Levels of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9, and Tissue Inhibitor of Matrix Metalloproteinase 1 and Their Applicability as Tumor Markers in Diagnoses of Cervical Cancer Based on ROC Analysis.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Będkowska GE; Gacuta E; Szmitkowski M; Ławicki S
Cancer Control; 2018; 25(1):1073274818789357. PubMed ID: 30037277
[TBL] [Abstract][Full Text] [Related]
3. Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer.
Ławicki S; Głażewska EK; Sobolewska M; Będkowska GE; Szmitkowski M
Ann Lab Med; 2016 May; 36(3):223-9. PubMed ID: 26915610
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patients.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Gacuta E; Szmitkowski M; Chrostek L; Ławicki S
Tumour Biol; 2018 Jul; 40(7):1010428318790363. PubMed ID: 30052166
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels and diagnostic utility of VEGF, MMP-2 and TIMP-2 in the diagnostics of breast cancer patients.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Biomarkers; 2017 Mar; 22(2):157-164. PubMed ID: 27775427
[TBL] [Abstract][Full Text] [Related]
6. Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor - VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer.
Zajkowska M; Lubowicka E; Fiedorowicz W; Szmitkowski M; Jamiołkowski J; Ławicki S
Pathol Oncol Res; 2019 Oct; 25(4):1477-1486. PubMed ID: 30387014
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of VEGF-A, VEGF B, and VEGFR-1 and applicability of these parameters as tumor markers in diagnosis of breast cancer.
Zajkowska M; Lubowicka E; Malinowski P; Szmitkowski M; Ławicki S
Acta Biochim Pol; 2018 Dec; 65(4):621-628. PubMed ID: 30543720
[TBL] [Abstract][Full Text] [Related]
8. Plasma Levels and Diagnostic Utility of M-CSF, MMP-2 and its Inhibitor TIMP-2 in the Diagnostics of Breast Cancer Patients.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Clin Lab; 2016 Sep; 62(9):1661-1669. PubMed ID: 28164586
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Power of Vascular Endothelial Growth Factor and Macrophage Colony-Stimulating Factor in Breast Cancer Patients Based on ROC Analysis.
Zajkowska M; Głażewska EK; Będkowska GE; Chorąży P; Szmitkowski M; Ławicki S
Mediators Inflamm; 2016; 2016():5962946. PubMed ID: 27445439
[TBL] [Abstract][Full Text] [Related]
10. VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve.
Ławicki S; Będkowska GE; Szmitkowski M
Growth Factors; 2013 Jun; 31(3):98-105. PubMed ID: 23688065
[TBL] [Abstract][Full Text] [Related]
11. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
12. Can VEGFR-3 be a better tumor marker for breast cancer than CA 15-3?
Zajkowska M; Gacuta E; Lubowicka E; Szmitkowski M; Ławicki S
Acta Biochim Pol; 2020 Mar; 67(1):25-29. PubMed ID: 32160452
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of proteolytic activity imbalance in breast cancer diagnosis.
Swellam M; Soliman HA; Abdelmaksoud MD; Nageeb AM; El Arab LR; Boshnak H
Cancer Biomark; 2014; 14(6):409-17. PubMed ID: 25335732
[TBL] [Abstract][Full Text] [Related]
14. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
Chen C; Chen Q; Dong Y; Liu X
Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
[TBL] [Abstract][Full Text] [Related]
15. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.
Tamura M; Oda M; Matsumoto I; Tsunezuka Y; Kawakami K; Ohta Y; Watanabe G
Ann Surg Oncol; 2004 Oct; 11(10):928-33. PubMed ID: 15383417
[TBL] [Abstract][Full Text] [Related]
16. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Ławicki S; Szmitkowski M; Wojtukiewicz M
Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
[TBL] [Abstract][Full Text] [Related]
17. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study.
Amati M; Tomasetti M; Scartozzi M; Mariotti L; Alleva R; Pignotti E; Borghi B; Valentino M; Governa M; Neuzil J; Santarelli L
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):163-70. PubMed ID: 18199721
[TBL] [Abstract][Full Text] [Related]
18. Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Onco Targets Ther; 2016; 9():911-9. PubMed ID: 26966379
[TBL] [Abstract][Full Text] [Related]
19. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.
Incorvaia L; Badalamenti G; Rini G; Arcara C; Fricano S; Sferrazza C; Di Trapani D; Gebbia N; Leto G
Anticancer Res; 2007; 27(3B):1519-25. PubMed ID: 17595770
[TBL] [Abstract][Full Text] [Related]
20. A novel serum metabolome score for breast cancer diagnosis.
Rashed R; Darwish H; Omran M; Belal A; Zahran F
Br J Biomed Sci; 2020 Oct; 77(4):196-201. PubMed ID: 32546046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
